ACADIA Pharmaceuticals (ACAD) Q1 2026 Preview: EPS Est. $0.08, Reports May 6

[ad_1] AlphaStreet Newsdesk powered by AlphaStreet Intelligence Related Coverage ACAD|EPS Est $0.08 (8 analysts)|Rev Est $280.3M|Reports 2026-05-06 Wall Street is looking for ACADIA Pharmaceuticals to deliver EPS of $0.08 on revenue of $280.3M when the biotechnology company reports Q1 2026…







